Familial amyotrophic lateral sclerosis
MONDO:0005144An instance of amyotrophic lateral sclerosis that is caused by an inherited modification of the individual's genome.
Also known as: hereditary amyotrophic lateral sclerosis
48 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to tackle rare brain disease
Disease control OngoingThis early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase: PHASE1, PHASE2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThis phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising Gene-Targeting drug for ALS enters final trial phase
Disease control OngoingThis study tests an experimental drug called ION363 in people with a rare, inherited form of ALS caused by FUS gene mutations. The goal is to see if the drug can slow the disease and help people live longer. About 89 participants will receive the drug via spinal injection. This i…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a common diabetes drug help fight ALS?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Over 24 weeks, 41 participants will take metformin to see if it reduces toxic proteins linked to the disease. The goal is to determine if metformin c…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New gene therapy targets rare, aggressive ALS
Disease control OngoingThis early-stage trial tests a gene therapy called AMT-162 in 20 adults with a specific genetic form of ALS (SOD1-ALS). The treatment is given as a single injection into the spinal fluid. The main goal is to check safety and tolerability, while also looking for early signs that i…
Phase: PHASE1, PHASE2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spit test could spot ALS early
Diagnosis OngoingThis study is testing whether a simple saliva sample can help diagnose amyotrophic lateral sclerosis (ALS). Researchers will analyze RNA in the saliva of 653 people, including ALS patients and healthy volunteers. If the test works, it could offer a faster, less invasive way to di…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
AI boosts brain scan accuracy in massive new trial
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI tool can help radiologists read brain CT and MRI scans more accurately and quickly. Researchers will compare how well doctors, AI alone, and doctors using AI together can spot abnormalities, urgent findings, and classify diseases. The goal is to red…
Sponsor: Yaou Liu • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Could a headset at home boost brain recovery? new study tests tDCS for stroke, tumors, and neurodegeneration
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a home-based brain stimulation device (tDCS) combined with activity therapy can help improve cognitive and language problems in people with stroke, brain tumors, or neurodegenerative conditions like Parkinson's or Alzheimer's. Fifty-five participants will…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Smart sleeve study aims to improve movement for nerve disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1000 people with upper motor neuron disease who are about to receive the Cionic Neural Sleeve. The sleeve uses electrical stimulation to help muscles contract at the right time during movement. Researchers will track changes in health-related quality of life us…
Phase: NA • Sponsor: Cionic, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC